Avacta Group (LON:AVCT) Releases Earnings Results

Avacta Group (LON:AVCT) announced its earnings results on Friday. The biotechnology company reported GBX (8.54) (($0.12)) EPS for the quarter, Digital Look Earnings reports. Avacta Group had a negative net margin of 114.45% and a negative return on equity of 74.00%.

Avacta Group Stock Performance

Shares of Avacta Group stock opened at GBX 32.41 ($0.44) on Friday. The business has a 50-day moving average of GBX 34.31 and a 200 day moving average of GBX 41.43. Avacta Group has a 12 month low of GBX 26 ($0.35) and a 12 month high of GBX 86.40 ($1.17). The stock has a market capitalization of £123.14 million, a price-to-earnings ratio of -4.17 and a beta of 1.12. The company has a debt-to-equity ratio of 52.53, a current ratio of 1.29 and a quick ratio of 4.96.

About Avacta Group

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics.
The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US.

Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).